Status and influencing factors of medication compliance in children with attention deficit hyperactivity disorder

doi:10.11852/zgetbjzz2018-26-10-14

Abstract

Abstract: Attention deficit hyperactivity disorder (ADHD) is the most common neuro-developmental disorder,which affects 5%~11% children around the world.Medication therapy is the preferred treatment for children aged over 6 years old with ADHD.It is considered that medication is effective for 70% of ADHD children.A variety of drugs have been used,such as methylphenidate and amphetamine,atomoxetine,guanfacine and clonidine.Medication adherence can be influenced by many factors,such as side effects of drugs,dosage form,growth velocity,families,and patients′ experience of taking medication,as well as sleep disorders.Doctors,parents and children cooperate to share information,decide on the medication treatment plan,monitor the effect of drug treatment and side effects,and actively carry out the combination of medical education and home school to implement behavior management and intervention,which will significantly improve the compliance,improve the treatment effect of medication treatment,promote the study of children with ADHD,improve overall promotion of social function and quality of life.

Key words: attention deficit hyperactivity disorder, pharmacotherapy, medication compliance, influencing factors

摘要： 注意缺陷多动障碍(ADHD)是儿童和青少年期最常见的神经发育障碍,约影响全世界5%～11%的儿童。药物治疗是6岁以上ADHD儿童首选方案,约70%患者药物治疗有效。多种药物已被应用于ADHD临床治疗,如盐酸哌甲酯和苯丙胺、盐酸托莫西汀及可乐定和胍法辛等。药物副作用、药物剂型、患儿生长速度、家庭因素、患儿用药体验、睡眠问题或障碍等多种因素均会影响药物依从性。医生、父母和患儿共享信息、商讨治疗方案、监测疗效和副作用,并积极开展医教结合、家校结合,实施行为管理和干预,有助于提高依从性、改善治疗效果,促进患儿学业成绩及社会功能、生活质量全面提升。

关键词: 注意缺陷多动障碍, 药物治疗, 依从性, 影响因素

CLC Number:

R179

ZHAO Qiu-xia, CHEN Li. Status and influencing factors of medication compliance in children with attention deficit hyperactivity disorder[J]. journal1, 2018, 26(10): 1096-1099.

赵秋霞, 陈立. 儿童注意缺陷多动障碍药物依从性及影响因素[J]. 中国儿童保健杂志, 2018, 26(10): 1096-1099.

0
/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://manu41.magtech.com.cn/Jwk_zgetbjzz/EN/10.11852/zgetbjzz2018-26-10-14

https://manu41.magtech.com.cn/Jwk_zgetbjzz/EN/Y2018/V26/I10/1096

References

[1] Dalsgaard S,Leckman JF,Mortensen PB,et al.Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder:a prospective cohort study[J].Lancet Psychiatry,2015,8(2):702-709.
[2] Centers for Disease Control and Prevention.Attention-deficit/hyperactivity disorder (ADHD):facts about ADHD[EB/OL].[2014-08-22]http://www.cdc.gov/ncbddd/adhd/facts.html.
[3] 郑毅,刘婧.中国注意缺陷多动障碍防治指南[M].2版.北京:中华医学电子音像出版社,2015.
[4] Wolraich M.ADHD:clinical practice guideline for the diagnosis,evaluation,and treatment of attention-deficit/hyperactivity disorder in children and adolescents[J].Pediatrics,2011,128(5):1007-1022.
[5] Ahmed R,Aslani P.Attention-defcit/hyperactivity disorder:an update on medication adherence and persistence in children,adolescents and adults[J].Expert Rev Pharmacoecon Outcomes Res,2013,13:791-815.
[6] De Sousa A,Kalra G.Drug therapy of attention deficit hyperactivity disorder:current trends[J].Mens Sana Monogr,2012,10(1):45-69.
[7] Sharma A, Couture J.A review of the pathophysiology,etiology,and treatment of attention-deficit hyperactivity disorder (ADHD)[J].Ann Pharmacother,2014,48(2):209-225.
[8] Wehmeier PM,Dittmann RW,Banaschewski T.Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice:Results from the COMPLY observational study[J].Atten Defic Hyperact Disord,2015,7(2):165-174.
[9] Cortese S,Holtmann M,Banaschewski T,et al.Practitioner review:current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents[J].Child Psychol Psychiatry,2013,54(3):227-246.
[10] Garg J, Arun P, Chavan BS.Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder[J].Indian Pediatr,2014,51(7):550-554.
[11] Hanwella R.Senanayake M,de Silva V.Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents:a meta-analysis[J].BMC Psychiatry,2011,11:176.
[12] Tzang RF,Wang YC.Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit/hyperactivity disorder[J].Psychiatry Clin Neurosci,2012,66(1):53-63.
[13] Childress AC,Kollins SH,Marraffino A,et al.Efficacy,safety,and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6-12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting[J].J Child Adolesc Psychopharmacol,2017,27(1):66-74.
[14] Poulton AS.Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder:a prospective cohort study[J].Int Clin Psychopharmacol,2016,31(2):93-99.
[15] Kratochvil CJ,Wilens TE,Greenhill LL,et al.Effects of longtermatomoxetine treatment for young children with attentiondeficit/hyperactivity disorder[J].Am Acad Child Adolesc Psychiatry,2006,45:919-927.
[16] Graham J,Bcanascheewski T,Buitelaar J,et al.European guidelines on managing adverse effects of medication for ADHD[J].Eur Child Adolesc Psychiatry,2011,20:17-37.
[17] Wigal SB,Childress A, Berry SA,et al.Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/Hyperactivity disorder[J].Child Adolesc Psychopharmacol,2017,27(8):690-699.
[18] Cheng JY,Ronald YL, Johnh SN, et al.Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis[J].Psychopharmacology,2007,194(2):197-209.
[19] Habel LA,Cooper WO,Sox CM,et al.ADHD medications and risk of serious cardiovascular events in young and middle-aged adults[J].JAMA,2011,306(24):2673-2683.
[20] Sayer GR.Acute and long-term cardiovascular effects of stimulant,guanfacine,and combination therapy for attention-deficit/hyperactivity disorder[J].Child Adolesc Psychopharmacol,2016,26(10):882-888.
[21] Cortese S,Pauei P,Arcieri R,et al.Safety of methylphenidate and atomoxetine in children with attention-deficit/hyperactivity disorder (ADHD):data from the Italian National ADHD Registry[J].CNS Drugs,2015,29(10):865-877.
[22] 范琼丽,陈立.注意缺陷多动障碍患儿共患睡眠问题和睡眠障碍的研究进展[J].中国实用儿科杂志,2016,31(5):391-395.
[23] Storebo OJ,Ramstad E,Krogh HB,et al.Methylphenidate for children and adolescents with attention deficit hyperactivity disorder(ADHD)[J].Cochrane Database Syst Rev,2015,11:CD009885.
[24] Becker SP,Froehlich TE,Epstein JN,et al.Effects of methyphenidate on sleep functioning in children with attention-deficit/hyperactivity disorder.[J].J Dev Behav Pediatr,2016,37(5):395-404.
[25] Hiscock H,Sciberras E,Mensah F,et al.Impact of a behavioural sleep intervention on symptoms and sleep in children with attention deficit hyperactivity disorder,and parental mental health:randomised controlled trial[J].BMJ,2015,350:h68.
[26] Hodgkins P,Sasane′ R,Christensen L,et al.Treatment outcomes with methylphenidate formulations among patients with ADHD:retrospective claims analysis of a managed care population[J].Curr Med Res Opin,2011,Suppl 2:53-62.
[27] Palli SR,Kamble PS,Chen H,et al.Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder[J].Child Adolesc Psychopharmacol,2012,22(2):139-148.
[28] Bai GN,Wang YF,Niu WY,et al.Effectiveness of a focused,brief psychoeducation program for parents of ADHD children:improvement of medication adherence and symptoms[J].Neuropsychiatr Dis Treat,2015,11:2721-2735.